{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-037654","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.696665+00:00","generated_at":"2026-05-23T02:00:16.706667+00:00","sec_items":["3.01","3.02","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ABVC receives Nasdaq delisting notice for low equity; raises $436K in stock sale","bullets":["Nasdaq notified ABVC on April 24 that stockholders' equity of $723,959 is below the $2.5M minimum for continued listing.","ABVC has 45 days to submit a compliance plan; if accepted, it may have until Oct 21, 2025 to regain compliance.","Sold 724,372 common shares to 15 non-U.S. persons for gross proceeds of ~$436,000 under Regulation S.","Each purchaser agreed to transfer voting rights to Chairman Eugene Jiang via a Voting Rights Proxy Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-037654","json":"https://secwatch.observer/filing/0001213900-25-037654.json","markdown":"https://secwatch.observer/filing/0001213900-25-037654.md","text":"https://secwatch.observer/filing/0001213900-25-037654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025037654/0001213900-25-037654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025037654/ea0239740-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:00:16.706667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}